-
公开(公告)号：US20190083529A1
公开(公告)日：2019-03-21
申请号：US16083865
申请日：2016-12-06
摘要： An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.
-
公开(公告)号：US20220401580A1
公开(公告)日：2022-12-22
申请号：US17776563
申请日：2020-11-12
摘要： Provided are nucleotide sequences encoding polypeptides with ribonuclease III activity, wherein the nucleotide sequences have been modified to reduce their regulation by miRNAs. In some embodiments, the nucleotide sequences are at least 50% and as much as 100% identical to SEQ ID NO: 20 or SEQ ID NO: 22, and/or encode polypeptides that are at least 90% percent identical to SEQ ID NO: 23. Also provided are vectors and host cells that include the nucleotide sequences, methods for expressing the nucleotide sequences in cells, tissues, and organs, which in some embodiments can be in the eye of a subject in need thereof, methods for preventing and/or treating development of diseases or disorders and/or for restoring undesirably low DICER1 expression using the nucleotide sequences, and pharmaceutical compositions that have the presently disclosed nucleotide sequences.
-
3.发明申请公开(公告)号：US20170304367A1
公开(公告)日：2017-10-26
申请号：US15523639
申请日：2015-10-29
发明人： Balamurali K. Ambati , Hironori Uehara , Judd Hoon
CPC分类号： A61K35/28 , A61K9/0048 , A61K38/00 , A61K38/1891 , A61K47/00 , A61K47/34 , A61K47/42 , A61K2300/00
摘要： Methods, compositions, and systems for treating ischemia-associated and other ocular conditions using cartilage oligo matrix protein-Angiopoietin 1 (COMP-Ang1) are disclosed and described.
-
4.发明授权Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization 有权Morpholino介导的可溶性Flt-1表达增加导致眼部和肿瘤新生血管形成减少公开(公告)号：US09506069B2
公开(公告)日：2016-11-29
申请号：US14394726
申请日：2013-04-19
IPC分类号： C12N15/11 , C12N15/113
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/11 , C12N2310/113 , C12N2310/3233 , C12N2320/33
摘要： Methods of inhibiting lymphangiogenesis and/or angiogenesis in a subject are provided. In one aspect, for example, a method of inhibiting angiogenesis in a subject can include binding an antisense morpholino to an mRNA splicing site of VEGFR1 selected from exon13_intron13 junction, intron13_exon14 junction, or a combination thereof. In another aspect, the morpholino includes a member selected from VEGFR1_MOe13, VEGFR1_MOi13, or a combination thereof.
摘要翻译： 提供了在受试者中抑制淋巴管生成和/或血管发生的方法。 在一个方面，例如，抑制受试者血管生成的方法可包括将反义吗啉代与选自外显子13_intron13连接，内含子13_exon14连接或其组合的VEGFR1的mRNA剪接位点结合。 在另一方面，吗啉代包括选自VEGFR1_MOe13，VEGFR1_MOi13或其组合的成员。
-
公开(公告)号：US11524032B2
公开(公告)日：2022-12-13
申请号：US16960077
申请日：2019-01-07
摘要： An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.
-
公开(公告)号：US20190008837A1
公开(公告)日：2019-01-10
申请号：US15844506
申请日：2017-12-15
IPC分类号： A61K31/437 , A61K9/127 , A61K45/06 , A61K9/00
摘要： Ophthalmic formulations and compositions employing pergolide to treat an ophthalmic or ocular condition are disclosed and described.
-
公开(公告)号：US09877973B2
公开(公告)日：2018-01-30
申请号：US15590868
申请日：2017-05-09
IPC分类号： A61M31/00 , A61K31/573 , A61K9/00 , A61K9/20
CPC分类号： A61K31/573 , A61F9/0017 , A61K9/0051 , A61K9/204 , A61K9/2054
摘要： An intraocular active agent delivery device can include an active agent homogenously combined with a biodegradable active agent matrix such that the entire delivery device is homogenous. The homogenous delivery device can have a shape and size to fit within a lens capsule or ciliary sulcus of an eye and provide a therapeutically effective amount of the active agent to the eye. The biodegradable active agent matrix can be formulated to provide sustained release of the therapeutically effective amount of the active agent during a release period. In some examples, the active agent can include dexamethasone.
-
公开(公告)号：US20170105932A1
公开(公告)日：2017-04-20
申请号：US15391666
申请日：2016-12-27
IPC分类号： A61K9/00 , A61K47/38 , A61K31/573 , A61K47/34
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/1647 , A61K9/1652 , A61K31/4709 , A61K31/5377 , A61K31/5575 , A61K31/573 , A61K31/7105
摘要： Devices, systems, and methods for delivery of an active agent from the lens capsule to a posterior segment of the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.
-
公开(公告)号：US20160040169A1
公开(公告)日：2016-02-11
申请号：US14358572
申请日：2012-11-15
IPC分类号： C12N15/113
CPC分类号： C12N15/1138 , C12N15/111 , C12N2310/11 , C12N2310/3233 , C12N2320/33
摘要： Various methods and compositions relating to vascular endothelial growth factor receptor 2 (VEGFR2) are provided. In one aspect, a method of increasing expression of the soluble form of VEGFR2 (sVEGFR2) in a subject can include binding an antisense morphoiino to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 niRNA is spliced into a sVEGFR2 isoform,
摘要翻译： 提供了与血管内皮生长因子受体2（VEGFR2）相关的各种方法和组合物。 一方面，增加受试者中可溶形式的VEGFR2（sVEGFR2）的表达的方法可包括将反义形态结合到VEGFR2 mRNA的外显子13-内含子13剪接位点，使得VEGFR2 niRNA被剪接成sVEGFR2同种型，
-
公开(公告)号：US20220288114A1
公开(公告)日：2022-09-15
申请号：US17626469
申请日：2020-07-13
IPC分类号： A61K33/34 , A61K9/00 , A61K31/46 , A61K31/216 , A61K31/5513 , A61K31/522 , A61P27/10
摘要： Opthalmic compositions are disclosed and described herein. In some embodiments, an ophthalmic composition can include as active agents a copper-containing agent and a secondary therapeutic agent in combination with a pharmaceutically acceptable carrier. The active agents can be present in amounts sufficient to treat myopic progression during a treatment period.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.021 秒)
